Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx's Phase Ib trial has demonstrated that a single administration of BL-1021 was safe and well tolerated.
Subscribe to our email newsletter
The study aimed at assessing the safety, tolerability and pharmacokinetics of a single administration of BL-1021 at doses between 10mg and 80mg.
The preliminary modeling of the pharmacokinetic data collected in this trial predicts that a once daily administration of BL-1021 at the dose levels assessed in the trial will enable reaching effective doses in patients.
BioLineRx CEO Kinneret Savitsky said they believe BL-1021 has the potential to provide improved efficacy without the side effects associated with many existing medications.
"We anticipate that the final results and analysis will confirm that BL-1021 has the competitive advantage of a once daily administration," Savitsky said.